Study on Glycyrrhizin for Prostate Cancer Treatment

Sponsor: University of Illinois at Chicago

Sponsor score: 0
Inactive

ClinicalTrials ID:NCT06378346

Provider View

This clinical trial is exploring the use of Glycyrrhizin, a compound, in men with untreated prostate cancer who are planning to have surgery. The study aims to see if taking Glycyrrhizin before surgery is safe and effective.

Patient Parameters

Program Overview

This study is testing Glycyrrhizin, a compound, in men with prostate cancer who have not yet received any treatment and are planning to undergo surgery to remove the prostate. Participants will be randomly assigned to receive one of two doses of Glycyrrhizin or no treatment for about six weeks before their surgery. The goal is to see if Glycyrrhizin is safe and if it has any effect on the cancer before surgery.

Description

This clinical trial is designed for men with prostate cancer who have not yet been treated and are planning to have surgery to remove the prostate (radical prostatectomy). Participants will be randomly assigned to one of three groups: one group will receive no treatment, the second group will take 75 mg of Glycyrrhizin daily, and the third group will take 150 mg of Glycyrrhizin daily. This treatment will last for about six weeks before the surgery. The study aims to determine if Glycyrrhizin is safe and if it has any impact on the cancer before surgery.

Eligibility Criteria

Inclusion Criteria

  • Must be 18 years or older.
  • Have a performance status score of 0, 1, or 2, indicating full activity or some restriction in strenuous activities.
  • Have a confirmed diagnosis of prostate cancer.
  • Be suitable for prostate surgery as determined by the surgical team.
  • Be able to provide written consent and agree to the use of personal health information for the study.
  • Agree to use barrier contraception during the study.

Exclusion Criteria

  • Have any other cancer that could interfere with the study treatment or its assessment.
  • Have received any cancer treatment, such as chemotherapy or radiation, within 30 days before starting the study.
  • Be taking medications that strongly affect the enzyme CYP3A4 within one week before starting the study.
  • Be taking medications that affect heart rhythm or have conditions that increase the risk of heart rhythm problems, such as uncontrolled high blood pressure or low levels of potassium or magnesium.

Get This Program In Your Inbox

Receive detailed information about this treatment opportunity to review with your healthcare provider.